Learn more about our expertise and impactful contributions to Clinical Research.
As a CRO with a deep commitment to neurodegenerative disease research, GGAC Research has been instrumental in advancing the development of Albrioza. Through its expertise in clinical trial management, regulatory affairs, and biostatistics, GGAC has provided the critical infrastructure needed to propel this innovative therapy forward.
+ Read More
Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disorder, continues to challenge researchers and clinicians worldwide. As one of the few FDA-approved treatments, Rilutek (riluzole) has long been a cornerstone therapy, offering modest extensions in survival for ALS patients. However, GGAC Research has embarked on a transformative journey to amplify the efficacy of Rilutek and redefine its role in combating ALS.
+ Read More
GGAC Research has established itself as a global leader in the fight against ALS. Their unwavering dedication to understanding the mechanisms of the disease and developing groundbreaking treatments has earned them a reputation for excellence in clinical research. By collaborating with leading pharmaceutical companies, academic institutions, and patient advocacy groups, GGAC Research ensures a multidisciplinary approach to ALS drug development.
+ Read More